Skip Navigation


Japanese Journal of Clinical Oncology Advance Access originally published online on December 30, 2008
Japanese Journal of Clinical Oncology 2009 39(2):92-96; doi:10.1093/jjco/hyn143
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
39/2/92    most recent
hyn143v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Yildirim, A.
Right arrow Articles by Tekin, S. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yildirim, A.
Right arrow Articles by Tekin, S. B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Author (2008). Published by Oxford University Press. All rights reserved

Serum Adiponectin Levels in Patients with Esophageal Cancer

Abdulkadir Yildirim1, Mehmet Bilici2, Kerim Çayir2, Vefa Yanmaz1, Serap Yildirim3 and Salim Basol Tekin2

1 Departments of Biochemistry
2 Internal Medicine Division of Medical Oncology
3 Physiology, Faculty of Medicine, Ataturk University, Erzurum, Turkey

For reprints and all correspondence: Abdulkadir Yildirim, Department of Biochemistry, Faculty of Medicine, Ataturk Universty, 25240 Erzurum, Turkey. E-mail: kadiryildirim{at}hotmail.com, kadir{at}atauni.edu.tr

Received September 21, 2008; accepted November 15, 2008

Objective: The aim of the study was to investigate a possible relationship between serum levels of adiponectin and clinicopathological characteristics in esophageal cancer. This is the first report evaluating serum adiponectin levels in patients with esophageal cancer.

Methods: Sixty-two patients with esophageal cancer and thirty healthy subjects were included in the study. Adiponectin levels were determined by an enzyme-linked immunosorbent assay kit.

Results: The mean serum adiponectin level in the cancer group was significantly low compared with the adiponectin level in the healthy control group. Furthermore, adiponectin levels of the patients gradually decreased with increase in tumor stage. The patients with adenocarcinoma of the esophagus had significantly lower values of serum adiponectin than patients with squamous cell carcinoma.

Conclusion: We concluded that decreased circulating adiponectin levels may play a role in the progression and/or development of esophageal cancers. However, for clinical use of serum adiponectin in terms of early diagnosis and treatment, further studies should be performed.

Key Words: adiponectin • esophageal adenocarcinoma • esophageal squamous cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.